← Back to Home

DMD Exon-Skipping Therapy Granted FDA Priority Review, With Meaningful Functional Benefit from Muscle Protein Signal the Key Question

Z-rostudirsen aims to deliver molecular therapy deeper into muscle and secure accelerated approval based on increased dystrophin; by January 2027, the FDA will assess whether this early signal is sufficient to clear the regulatory threshold.

By SURL BioNews

For patients with Duchenne muscular dystrophy (DMD), the central treatment challenge is not only correcting the genetic message, but also ensuring that the drug actually reaches widely distributed muscles. The US Food and Drug Administration (FDA) has accepted Dyne Therapeutics’ biologics license application and granted priority review to the exon 51-skipping therapy zeleciment rostudirsen (z-rostudirsen), with a target action date of January 21, 2027.

This decision means the application is sufficiently complete to enter formal review; it does not mean the therapy has been approved. The FDA must still evaluate its safety, efficacy, manufacturing quality, and overall benefit-risk profile. Priority review shortens the standard review period from approximately 10 months to approximately 6 months. The application is proceeding through the accelerated approval pathway, using dystrophin expression in muscle as a surrogate endpoint.

DMD is caused by variants in the DMD gene, resulting in a lack of the dystrophin needed to maintain muscle fiber stability. Z-rostudirsen is limited to patients whose genetic message can be reconnected by skipping exon 51. It links an exon-skipping molecule to an antigen-binding fragment and is designed to improve the drug’s entry into muscle cells, enabling the cells to produce a shorter protein that may still retain some function. The proposed dosing regimen is an intravenous infusion once every 4 weeks.

The application is primarily based on the Phase 1/2 DELIVER trial. According to a summary by NeurologyLive, the registrational expansion cohort included 32 boys aged 4 to 16, of whom 24 received 20 mg/kg of the drug and 8 received placebo. After 6 months of treatment, muscle content-adjusted dystrophin relative to baseline reached 5.46% of normal, while the unadjusted mean absolute expression level was 2.87% of normal. The report also stated that all six prespecified functional measures showed nominal improvements, including the speed of rising from the floor and walking/running 10 meters, but the small sample and short follow-up are insufficient to demonstrate that these differences can alter the long-term course of the disease.

Safety data covered 86 participants and a combined exposure of 113 patient-years. Related adverse events were mostly mild to moderate, with fever and headache the most common. However, the central question for accelerated approval is whether the increase in protein can reliably predict lasting improvements in walking, breathing, and the ability to perform daily activities. Regulators will also examine trial analyses, individual variability, and manufacturing consistency, rather than drawing conclusions from a single biomarker alone.

To address this evidence gap, the Phase 3 FORZETTO confirmatory trial has been registered and is listed as recruiting, with plans to enroll approximately 90 ambulatory male patients aged 4 to 18 who are eligible for exon 51 skipping. Participants will first receive 72 weeks of randomized, placebo-controlled treatment, followed by a 96-week open-label extension. The primary endpoint is the change in speed of rising from the floor at Week 73; the trial will also track the NSAA scale, the 10-meter walk/run, respiratory function, and safety. If the FDA first grants accelerated approval, this trial will be responsible for confirming clinical benefit and supporting conversion to traditional approval.

References

  1. Dyne Therapeutics
  2. Parent Project Muscular Dystrophy
  3. NeurologyLive
  4. ClinicalTrials.gov